title: Enhancing and initiating phage-based therapies.
abstract: Drug development has typically been a primary foundation of strategy for systematic, long-range management of pathogenic cells. However, drug development is limited in speed and flexibility when response is needed to changes in pathogenic cells, especially changes that produce drug-resistance. The high replication speed and high diversity of phages are potentially useful for increasing both response speed and response flexibility when changes occur in either drug resistance or other aspects of pathogenic cells. We present strategy, with some empirical details, for (1) using modern molecular biology and biophysics to access these advantages during the phage therapy of bacterial infections, and (2) initiating use of phage capsid-based drug delivery vehicles (DDVs) with procedures that potentially overcome both drug resistance and other present limitations in the use of DDVs for the therapy of neoplasms. The discussion of phage therapy includes (a) historical considerations, (b) changes that appear to be needed in clinical tests if use of phage therapy is to be expanded, (c) recent work on novel phages and its potential use for expanding the capabilities of phage therapy and (d) an outline for a strategy that encompasses both theory and practice for expanding the applications of phage therapy. The discussion of DDVs starts by reviewing current work on DDVs, including work on both liposomal and viral DDVs. The discussion concludes with some details of the potential use of permeability constrained phage capsids as DDVs.
authors.affiliation: Department of Biochemistry; The University of Texas Health Science Center ; San Antonio, TX USA.
authors.forename: Philip
authors.initials: P
authors.lastname: Serwer
authors.affiliation: Department of Biochemistry; The University of Texas Health Science Center ; San Antonio, TX USA.
authors.forename: Elena T
authors.initials: ET
authors.lastname: Wright
authors.affiliation: Department of Biochemistry and Molecular Biology; Baylor College of Medicine ; Houston, TX USA.
authors.forename: Juan T
authors.initials: JT
authors.lastname: Chang
authors.affiliation: Department of Biochemistry and Molecular Biology; Baylor College of Medicine ; Houston, TX USA.
authors.forename: Xiangan
authors.initials: X
authors.lastname: Liu
keywords: biofilms; cancer therapy; cryo-electron microscopy; drug-delivery vehicles; infectious diseases; novel bacteriophages